ctions caused by campylobacter fetus. brucellosis due to brucella species (in conjunction with streptomycin). bartonellosis due to bartonella bacilliformis. granuloma inguinale caused by klebsiella granulomatis. minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: escherichia coli. enterobacter aerogenes. shigella species. acinetobacter species. respiratory tract infections caused by haemophilus influenzae. respiratory tract and urinary tract infections caused by klebsiella species. minocycline hydrochloride capsules, usp are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: upper respiratory tract infections caused by streptococcus pneumoniae. skin and skin structure infections caused by staphylococcus aureus. (note: minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) when penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: uncomplicated urethritis in men due to neisseria gonorrhoeae and for the treatment of other gonococcal infections. infections in women caused by neisseria gonorrhoeae. syphilis caused by treponema pallidum subspecies pallidum. yaws caused by treponema pallidum subspecies pertenue. listeriosis due to listeria monocytogenes. anthrax due to bacillus anthracis. vincent's infection caused by fusobacterium fusiforme. actinomycosis caused by actinomyces israelii. infections caused by clostridium species. in acute intestinal amebiasis, minocycline may be a useful adjunct to amebicides. in severe acne, minocycline may be useful adjunctive therapy. oral minocycline is indicated in the treatment of asymptomatic carriers of neisseria meningitidis to eliminate meningococci from the nasopharynx. in order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. it is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. oral minocycline is not indicated for the treatment of meningococcal infection. although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by mycobacterium marinum. to reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules, usp and other antibacterial drugs, minocycline hydrochloride capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

ved in premature human infants given oral tetracycline in doses of 25 mg/kg every six hours. this reaction was shown to be reversible when the drug was discontinued. use in pregnancy results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). evidence of embryotoxicity has been noted in animals treated early in pregnancy. dermatologic reaction drug rash with eosinophilia and systemic symptoms (dress) including fatal cases has been reported with minocycline use. if this syndrome is recognized, the drug should be discontinued immediately. antianabolic action the antianabolic action of the tetracyclines may cause an increase in blood urea nitrogen (bun). while this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline may lead to azotemia, hyperphosphatemia, and acidosis. under such conditions, monitoring of creatinine and bun is recommended, and the total daily dosage should not exceed 200 mg in 24 hours (see dosage and administration). if renal impairment exists, even usual oral or parenteral doses may lead to systemic accumulation of the drug and possible liver toxicity. photosensitivity photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. this has been reported with minocycline. central nervous system central nervous system side effects including lightheadedness, dizziness, or vertigo have been reported with minocycline therapy. patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. these symptoms may disappear during therapy and usually disappear rapidly when the drug is discontinued. clostridium difficile associated diarrhea clostridium difficile associated diarrhea (cdad) has been reported with use of nearly all antibacterial agents, including minocycline hydrochloride, and may range in severity from mild diarrhea to fatal colitis. treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of c. difficile. c. difficile produces toxins a and b which contribute to the development of cdad. hypertoxin-producing strains of c. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. cdad must be considered in all patients who present with diarrhea following antibiotic use. careful medical history is necessary since cdad has been reported to occur over two months after the administration of antibacterial agents. if cdad is suspected or confirmed, ongoing antibiotic use not directed against c. difficile may need to be discontinued. appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of c. difficile, and surgical evaluation should be instituted as clinically indicated. intracranial hypertension intracranial hypertension (ih, pseudotumor cerebri) has been associated with the use of tetracyclines including minocycline hydrochloride. clinical manifestations of ih include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. women of childbearing age who are overweight or have a history of ih are at greater risk for developing tetracycline-associated ih. concomitant use of isotretinoin and minocycline hydrochloride should be avoided because isotretinoin is also known to cause pseudotumor cerebri. although ih typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. if visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. since intracranial pressure can remain elevated for weeks after drug cessation, patients should be monitored until they stabilize.

and anorectal infections in men: 200 mg initially, followed by 100 mg every 12 hours for a minimum of 4 days, with post-therapy cultures within 2 to 3 days. in the treatment of uncomplicated gonococcal urethritis in men, 100 mg every 12 hours for 5 days is recommended. for the treatment of syphilis, the usual dosage of minocycline hydrochloride should be administered over a period of 10 to 15 days. close follow-up, including laboratory tests, is recommended. in the treatment of meningococcal carrier state, the recommended dosage is 100 mg every 12 hours for 5 days. mycobacterium marinum infections: although optimal doses have not been established, 100 mg every 12 hours for 6 to 8 weeks have been used successfully in a limited number of cases. uncomplicated urethral, endocervical, or rectal infection in adults caused by chlamydia trachomatis or ureaplasma urealyticum: 100 mg orally, every 12 hours for at least 7 days. ingestion of adequate amounts of fluids along with capsule and tablet forms of drugs in the tetracycline class is recommended to reduce the risk of esophageal irritation and ulceration. the pharmacokinetics of minocycline in patients with renal impairment (clcr <80 ml/min) have not been fully characterized. current data are insufficient to determine if a dosage adjustment is warranted. the total daily dosage should not exceed 200 mg in 24 hours. however, due to the antianabolic effect of tetracyclines, bun and creatinine should be monitored (see warnings).

liver failure have been reported (see precautions). skin: alopecia, erythema nodosum, hyperpigmentation of nails, pruritus, toxic epidermal necrolysis, vasculitis, maculopapular rash and erythematous rash. exfoliative dermatitis has been reported. fixed drug eruptions have been reported. lesions occurring on the glans penis have caused balanitis. erythema multiforme and stevens-johnson syndrome have been reported. photosensitivity is discussed above (see warnings). pigmentation of the skin and mucous membranes has been reported. respiratory: cough, dyspnea, bronchospasm, exacerbation of asthma, and pneumonitis. renal toxicity: interstitial nephritis. elevations in bun have been reported and are apparently dose related (see warnings). reversible acute renal failure has been reported. musculoskeletal: arthralgia, arthritis, bone discoloration, myalgia, joint stiffness, and joint swelling. hypersensitivity reactions: urticaria, angioneurotic edema, polyarthralgia, anaphylaxis/anaphylactoid reaction (including shock and fatalities), anaphylactoid purpura, myocarditis, pericarditis, exacerbation of systemic lupus erythematosus and pulmonary infiltrates with eosinophilia have been reported. a transient lupus-like syndrome and serum sickness-like reactions also have been reported. blood: agranulocytosis, hemolytic anemia, thrombocytopenia, leukopenia, neutropenia, pancytopenia, and eosinophilia have been reported. central nervous system: convulsions, dizziness, hypesthesia, paresthesia, sedation, and vertigo. bulging fontanels in infants and benign intracranial hypertension (pseudotumor cerebri) in adults have been reported (see precautions - general). headache has also been reported. other: thyroid cancer has been reported in the postmarketing setting in association with minocycline products. when minocycline therapy is given over prolonged periods, monitoring for signs of thyroid cancer should be considered. when given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. cases of abnormal thyroid function have been reported. tooth discoloration in children less than 8 years of age (see warnings) and also in adults has been reported. oral cavity discoloration (including tongue, lip, and gum) has been reported. tinnitus and decreased hearing have been reported in patients on minocycline hydrochloride. the following syndromes have been reported. in some cases involving these syndromes, death has been reported. as with other serious adverse reactions, if any of these syndromes are recognized, the drug should be discontinued immediately: hypersensitivity syndrome consisting of cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. fever and lymphadenopathy may be present. lupus-like syndrome consisting of positive antinuclear antibody; arthralgia, arthritis, joint stiffness, or joint swelling; and one or more of the following: fever, myalgia, hepatitis, rash, and vasculitis. serum sickness-like syndrome consisting of fever; urticaria or rash; and arthralgia, arthritis, joint stiffness, or joint swelling and lymphadenopathy. eosinophilia may be present. to report suspected adverse reactions, contact aurobindo pharma usa, inc. at 1-866-850-2876 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

tion. the urinary and fecal recovery of minocycline when administered to 12 normal volunteers was one-half to one-third that of other tetracyclines. microbiology mechanism of action the tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. the tetracyclines, including minocycline, have a similar antimicrobial spectrum of activity against a wide range of gram-positive and gram-negative organisms. cross-resistance of these organisms to tetracycline is common. antimicrobial activity minocycline has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the indications and usage section: gram-positive bacteria bacillus anthracis listeria monocytogenes staphylococcus aureus streptococcus pneumoniae gram-negative bacteria bartonella bacilliformis brucella species klebsiella granulomatis campylobacter fetus francisella tularensis haemophilus ducreyi vibrio cholerae yersinia pestis acinetobacter species enterobacter aerogenes escherichia coli haemophilus influenzae klebsiella species neisseria gonorrhoeae neisseria meningitidis shigella species other microorganisms actinomyces species borrelia recurrentis chlamydophila psittaci chlamydia trachomatis clostridium species entamoeba species fusobacterium nucleatum subspecies fusiforme mycobacterium marinum mycoplasma pneumoniae propionibacterium acnes rickettsiae treponema pallidum subspecies pallidum treponema pallidum subspecies pertenue ureaplasma urealyticum susceptibility testing for specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by fda for this drug, please see: https://www.fda.gov/stic.

°f); excursions permitted to 15° to 30°c (59° to 86°f) [see usp controlled room temperature]. protect from light, moisture, and excessive heat. dispense in a tight, light-resistant container as defined in the usp.